What Is Retatrutide?
Retatrutide is a novel triple-agonist peptide that simultaneously activates three incretin-related receptors: GIP, GLP-1, and glucagon. This makes it the first research compound to engage all three metabolic pathways in a single molecule — a significant advance beyond dual-agonists like tirzepatide.
The addition of glucagon receptor agonism is what distinguishes retatrutide from its predecessors. While glucagon has traditionally been viewed primarily as a counter-regulatory hormone that raises blood glucose, emerging research reveals its broader role in energy expenditure, lipid metabolism, and hepatic fat reduction.
Triple Receptor Mechanism
GLP-1 receptor: Reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion — the same pathway targeted by semaglutide and liraglutide.
GIP receptor: Promotes insulin secretion, influences adipose tissue metabolism, and may have direct effects on brain appetite circuits — the same co-agonism mechanism in tirzepatide.
Glucagon receptor: The novel addition. Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and enhances thermogenesis. In research settings, this third pathway appears to drive additional metabolic benefits, particularly regarding liver fat content and resting metabolic rate.
Clinical Research Highlights
The phase 2 clinical trial program for retatrutide produced remarkable results. At the 48-week mark, subjects receiving the highest doses demonstrated mean body weight reductions exceeding 24% — the largest reported for any anti-obesity pharmacotherapy in a clinical trial to date.
Perhaps more significant for research purposes, retatrutide showed dramatic effects on liver fat content. Subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) showed mean reductions in liver fat exceeding 80% at 48 weeks, with a majority achieving complete resolution of hepatic steatosis. This has opened an entirely new research avenue for GLP-1/GIP/glucagon triple agonism in liver disease models.
Research Applications
Retatrutide unique triple-agonist profile makes it a valuable research tool for several areas: metabolic syndrome pathway studies comparing dual vs. triple receptor activation, hepatic steatosis and MASLD research models, energy expenditure and thermogenesis investigations, and understanding the interplay between incretin and glucagon signaling in metabolic homeostasis.
CertaPeptides offers retatrutide 50mg research vials with ≥99% HPLC purity and batch-specific COAs.
For research use only. Not intended for human consumption.